3 Profitable Stocks We’re Skeptical Of

Barchart·06/15/2026 03:52:16

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

Profits are valuable, but they’re not everything. At StockStory, we help you identify the companies that have real staying power. Keeping that in mind, here are three profitable companies to steer clear of and a few better alternatives.

GoDaddy (GDDY)

Trailing 12-Month GAAP Operating Margin: 23.7%

Known for its memorable Super Bowl commercials that put it on the map, GoDaddy (NYSE:GDDY) is a domain registrar and web services provider that helps entrepreneurs establish an online presence through domain registration, website building, hosting, and e-commerce tools.

Why Should You Dump GDDY?

1. Offerings struggled to generate meaningful interest as its average billings growth of 3.6% over the last year did not impress
2. Estimated sales growth of 5.9% for the next 12 months implies demand will slow from its two-year trend
3. Operating margin improvement of 3 percentage points over the last year demonstrates its ability to scale efficiently

GoDaddy’s stock price of $76.24 implies a valuation ratio of 1.9x forward price-to-sales. If you’re considering GDDY for your portfolio, see our FREE research report to learn more.

Inspired (INSE)

Trailing 12-Month GAAP Operating Margin: 12.6%

Specializing in digital casino gaming, Inspired (NASDAQ:INSE) is a provider of gaming hardware, virtual sports platforms, and server-based gaming systems.

Why Do We Avoid INSE?

1. Lackluster 12.1% annual revenue growth over the last five years indicates the company is losing ground to competitors
2. Responsiveness to unforeseen market trends is restricted due to its substandard operating margin profitability
3. Poor free cash flow margin of 5.1% for the last two years limits its freedom to invest in growth initiatives, execute share buybacks, or pay dividends

At $8.31 per share, Inspired trades at 27.8x forward P/E. Read our free research report to see why you should think twice about including INSE in your portfolio.

Integra LifeSciences (IART)

Trailing 12-Month GAAP Operating Margin: 10.2%

Founded in 1989 as a pioneer in regenerative medicine technology, Integra LifeSciences (NASDAQ:IART) develops and manufactures medical technologies for neurosurgery, wound care, and surgical reconstruction, including regenerative tissue products and surgical instruments.

Why Do We Steer Clear of IART?

1. Core business is underperforming as its organic revenue has disappointed over the past two years, suggesting it might need acquisitions to stimulate growth
2. Performance over the past five years shows its incremental sales were much less profitable, as its earnings per share fell by 2.4% annually
3. High net-debt-to-EBITDA ratio of 5× could force the company to raise capital on unfavorable terms if market conditions deteriorate

Integra LifeSciences is trading at $17.56 per share, or 7.1x forward P/E. Dive into our free research report to see why there are better opportunities than IART.

Stocks We Like More

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.